Emerging Therapies for Childhood Leukemia

Childhood leukemia remains a significant focus of cancer research, with ongoing efforts to discover novel therapies to improve survival rates and minimize long-term side effects. Recent advancements in targeted therapies, such as CAR T-cell therapy and small molecule inhibitors, have shown promise in treating relapsed or refractory leukemia. These therapies work by precisely targeting cancer cells, sparing normal cells and reducing toxicity. Additionally, research into genetic mutations and biomarkers has led to the identification of new therapeutic targets, enabling more personalized treatment strategies. The goal is to enhance cure rates while minimizing the impact of treatment on the child’s development and quality of life.